East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisolone Tablets USP, 5 mg. Aurobindo Pharma’s Prednisolone Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Prednisolone Tablets manufactured by Watson Laboratories Inc.

Prednisolone Tablets are indicated in the following conditions:

• Endocrine disorders
• Rheumatic disorders
• Collagen diseases
• Dermatologic diseases
• Allergic states
• Ophthalmic diseases
• Respiratory diseases
• Hematologic disorders
• Neoplastic diseases
• Edematous states
• Gastrointestinal diseases
• Nervous system
• Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.